![Endothelin: 20 years from discovery to therapy This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin. Endothelin: 20 years from discovery to therapy This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.](https://cdnsciencepub.com/cms/10.1139/Y08-059/asset/images/large/y08-059f1.jpeg)
Endothelin: 20 years from discovery to therapy This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.
![Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determ ... - Analytical Methods (RSC Publishing) DOI:10.1039/C5AY00651A Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determ ... - Analytical Methods (RSC Publishing) DOI:10.1039/C5AY00651A](https://pubs.rsc.org/image/article/2015/AY/c5ay00651a/c5ay00651a-f2_hi-res.gif)
Pharmacological and therapeutic properties of new derivatives of renin inhibitors and endothelin receptor antagonists, and the methods of their determ ... - Analytical Methods (RSC Publishing) DOI:10.1039/C5AY00651A
![JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy](https://pub.mdpi-res.com/jcm/jcm-09-00824/article_deploy/html/images/jcm-09-00824-g004.png?1585797123)
JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
![Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension - Kazuya Miyagawa, Noriaki Emoto, 2014 Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension - Kazuya Miyagawa, Noriaki Emoto, 2014](https://journals.sagepub.com/cms/10.1177/1753944714541511/asset/images/large/10.1177_1753944714541511-fig1.jpeg)
Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension - Kazuya Miyagawa, Noriaki Emoto, 2014
![Cureus | Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review Cureus | Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review](https://assets.cureus.com/uploads/figure/file/266716/lightbox_8e887b00211d11ec8d330b85c0fdf736-Webp.net-resizeimage-1-.png)
Cureus | Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review
![Targeted therapies: endothelin receptor antagonists | Advances in The Management of Pulmonary Arterial Hypertension Targeted therapies: endothelin receptor antagonists | Advances in The Management of Pulmonary Arterial Hypertension](https://www.futuremedicine.com/cms/10.2217/ebo.13.239/asset/images/medium/figure1.gif)
Targeted therapies: endothelin receptor antagonists | Advances in The Management of Pulmonary Arterial Hypertension
![Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.5b01781/asset/images/large/jm-2015-01781t_0008.jpeg)
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis | Journal of Medicinal Chemistry
![JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy](https://www.mdpi.com/jcm/jcm-09-00824/article_deploy/html/images/jcm-09-00824-g001.png)
JCM | Free Full-Text | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy
![Dual endothelin receptor antagonism increases resting energy expenditure in people with increased adiposity | American Journal of Physiology-Endocrinology and Metabolism Dual endothelin receptor antagonism increases resting energy expenditure in people with increased adiposity | American Journal of Physiology-Endocrinology and Metabolism](https://journals.physiology.org/cms/10.1152/ajpendo.00349.2021/asset/images/medium/e-00349-2021r01.png)
Dual endothelin receptor antagonism increases resting energy expenditure in people with increased adiposity | American Journal of Physiology-Endocrinology and Metabolism
![Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? | European Respiratory Society Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? | European Respiratory Society](https://erj.ersjournals.com/content/erj/52/2/1801287/F1.large.jpg)
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? | European Respiratory Society
![Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? - ScienceDirect Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0024320512004122-gr1.jpg)